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Abstract
Purpose—The leptin-signaling pathway and other genes involved with energy homeostasis (EH), 
have been examined in relation to breast cancer risk as well as to obesity. We test the hypothesis 
that genetic variation in EH genes influences survival after diagnosis with breast cancer and that 
body mass index (BMI) will modify that risk.
Methods—We evaluated associations between 10 energy homeostasis genes and survival among 
1186 non-Hispanic white (NHW) and 1155 Hispanic/Native American women diagnosed with 
breast cancer. Percent Native American (NA) ancestry was determined from 104 Ancestry 
Informative Markers. Adaptive rank truncation product (ARTP) was used to determine gene and 
pathway significance.
Results—The overall EH pathway was marginally significant for all-cause mortality among 
women with low NA ancestry (PARTP = 0.057). Within the pathway, ghrelin (GHRL) and leptin 
receptor (LEPR) were significantly associated with all-cause mortality (PARTP = 0.035 and 0.007, 
respectively). The EH pathway was significantly associated with breast cancer-specific mortality 
among women with low NA ancestry (PARTP = 0.038). Three genes, cholecystokinin (CCK), 
GHRL, and LEPR were significantly associated with breast cancer-specific mortality among 
women with low NA ancestry (PARTP = 0.046, 0.015, and 0.046, respectively) while neuropeptide 
Y (NPY) was significantly associated with breast cancer-specific mortality among women with 
higher NA ancestry (PARTP = 0.038). BMI did not modify these associations.
Conclusions—Our data support our hypothesis that certain EH genes influence survival after 
diagnosis with breast cancer; associations appear to be most important among women with low 
NA ancestry.
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The leptin-signaling pathway is positively associated with obesity and has been shown to 
stimulate the growth of human breast cancer cells. The biological effects of leptin (LEP) are 
exerted through binding to the leptin receptor (LEPR). This receptor is expressed in a variety 
of immune cells and has been shown in breast cancer cell lines to have direct communication 
with estrogen receptor alpha (1). The leptin-signaling pathway, along with other energy 
homeostasis (EH) genes, have been examined in relation to breast cancer risk as well as to 
obesity (2). Cocaine and amphetamine regulated transcript protein (CARTPT), 
cholecystokinin (CCK), leptin (LEP), leptin receptor (LEPR), Membrane Bound O-
Acyltransferase Domain Containing 4 (MBOAT4), melanocortin 4 receptor (MC4R), 
neuropeptide Y (NPY), and proopiomelanocortin (POMC) ghrelin/obestatin prepropeptide 
(GHRL), are neuropeptides involved in the regulation of appetite and satiety. Ghrelin/
obestatin prepropeptide (GHRL) is involved in energy homeostasis and regulation of body 
weight through its influence on satiety. Polymorphisms in GHRL have been linked to breast 
cancer risk as well as to obesity and insulin levels (3). GHRL Membrane Bound O-
Acyltransferase Domain Containing 4 (MBOAT4) codes the ghrelin O-acyltransferase 
(GOAT) enzyme that acrylates ghrelin to enable its endocrine actions(4).
While studies have examined the relationship between EH genes with breast cancer risk, 
there is rationale for their involvement in survival after diagnosis with breast cancer. Variants 
in LEP and LEPR have been associated with breast cancer-specific mortality (5). Given the 
role of EH genes in maintaining body weight, serum levels of adiponectin have been 
associated with insulin resistance and differences in adipokines such as adiponectin levels 
have been associated with survival (6). LEP, NPY, and GHRL levels have been shown to 
regulate growth hormone secretion and promote cell growth (7-11). LEP has been shown to 
have angiogenesis properties and stimulate growth of human breast cancer cells (5, 12, 13). 
Several neuropeptides have been hypothesized as playing a role in cachexia, or extreme 
weight loss or wasting after cancer diagnosis (14). Cachexia is associated with decreased 
survival.
In this study we examine the relationship between ten EH genes and all-cause and breast 
cancer-specific mortality. These genes were selected because of their association with energy 
homeostasis and cancer and/or obesity. We evaluate associations by genetic ancestry, given 
differences in risk associated with these genes by Native American (NA) ancestry (15). 
Additionally, NA ancestry has been shown to be an important determinate of breast cancer 
risk among population of mixed Caucasian and NA ancestry, with women with greater NA 
ancestry having lower incidence of breast cancer than women of European ancestry (16, 17) 
We evaluate the modifying effects of body mass index (BMI) on survival given the 
relationship between these genes and BMI and breast cancer (15, 18-20).
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This analysis from the Breast Cancer Health Disparities Study includes participants with 
information on survival from two population-based case-control studies, the 4-Corners 
Breast Cancer Study (4-CBCS) and the San Francisco Bay Area Breast Cancer Study 
(SFBCS) (17). In the 4-CBCS, participants were between 25 and 79 years of age with a 
histologically confirmed diagnosis of first primary invasive breast cancer (n=1391) between 
October 1999 and May 2004 (21) and lived in one of the four 4-Corners' states of Arizona, 
Colorado, New Mexico, or Utah. The SFBCS included women aged 35 to 79 years from the 
San Francisco Bay Area diagnosed with a first primary histologically confirmed invasive 
breast cancer (n= 946) between April 1997 and April 2002 (22, 23). All participants 
provided informed written consent prior to participation. This study was approved by the 
Institutional Review Boards for Human Subjects at the University of Utah and the Cancer 
Prevention Institute of California.
Data Harmonization
Data were harmonized across study-specific questionnaires (17). Women were considered 
post-menopausal if they reported either a natural menopause or if they reported taking 
hormone therapy (HT) and were still having periods or were at or above the 95th percentile 
of age for those who reported having a natural menopause (i.e., ≥ 12 months since their last 
period); others were classified as pre-menopausal. Women who reported having a 
hysterectomy were considered post-menopausal. BMI (kg/m2) was calculated based on self-
reported weight during the reference year or weight measured at interview (controls only) if 
weight during the reference year was not available. Height was based on measured height at 
interview or self-reported height if the measurement was declined. Categories of BMI were 
normal BMI (<25.0 kg/m2), overweight (25.0-29.9 kg/m2), or obese (≥30 kg/m2). Parity was 
defined as the number of total pregnancies.
Genetic Data
DNA was extracted from either whole blood or mouthwash samples. Genotyping was 
completed for 933 women from the 4-CBCS who self-identified as non-Hispanic white 
(NHW), 412 Hispanic, 8 NA, 14 NHW/Hispanic, 10 NHW/NA, 10 Hispanic/NA, and 4 
NHW/Hispanic/NA and for 252 women from the SFBCS who self-reported being NHW and 
694 who reported being Hispanic. Women who self-identified as Hispanic and/or NA were 
considered Hispanic/NA for the analysis. A tagSNP approach was used to characterize 
variation across candidate genes. TagSNPs were selected using the following parameters: 
linkage disequilibrium (LD) blocks were defined using a Caucasian LD map and an r2=0.8 
based on hapmap data; minor allele frequency (MAF) >0.1; range of -1500 bps from the 
initiation codon to +1500 bps from the termination codon; and one SNP/LD bin. Coding and 
non-coding SNPs were included as were both the 5′UTR and 3′UTR areas. We used 104 
Ancestry Informative Markers (AIMs) to distinguish European and NA ancestry in the study 
population (17). All markers were genotyped using a multiplexed bead array assay format 
based on GoldenGate chemistry (Illumina, San Diego, California). In the current analysis we 
evaluated tagSNPs for ADIPOQ (12 SNPs), CARTPT (5 SNPs), CCK (4 SNPs), GHRL (8 
SNPs), LEP (9 SNPs), LEPR (27 SNPs), MBOAT4 (1 SNP), MC4R (3 SNPs), NPY (4 
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SNPs), and POMC (5 SNPs). These genes and SNPs are described in online Supplement 
Table 1.
Tumor Characteristics and Survival
Data on survival were available from local cancer registries through December of 2013 and 
included date of death or last follow-up (month and year), underlying cause of death, and 
SEER summary stage of disease at time of diagnosis. Disease stage was obtained from 
tumor registries and was coded based on complete pathological reports that included extent 
of disease, node involvement, and metastasis. Survival (in months) was calculated as the 
difference between diagnosis date and date of death or last follow-up.
Statistical Methods
The program STRUCTURE was used to compute individual ancestry for each study 
participant assuming two founding populations (24, 25). A three-founding population model 
was assessed, but did not fit the population structure with the same level of repeatability and 
correlation among runs as the two-founding population model. Participants were classified 
by level of percent NA genetic ancestry. Women who self-reported as being NHW had a low 
percentage of NA ancestry. Assessment across categories of ancestry was done using cut-
points based on the distribution of genetic ancestry in the control population with the goal of 
creating distinct ancestry groups that had sufficient power to assess associations. Two strata 
of ≤28% and >28% of NA ancestry were used to evaluate associations.
Associations between SNPs and all-cause and breast cancer-specific mortality were 
evaluated using Cox proportional hazards models to obtain multivariate hazard ratios (HR) 
and 95% confidence intervals (CI) for all women and within strata of NA genetic ancestry 
using SAS version 9.4 (SAS Institute, Cary, NC). Individuals were censored when they were 
lost to follow-up or if they died of causes other than breast cancer when examining breast 
cancer-specific mortality. All SNPs were evaluated as a co-dominant model, and if initial 
analysis suggested too few homozygote variants or the dominant model appeared to fit the 
data then a dominant model was used. In other instances where a recessive model appeared 
to fit the data, it was used to evaluate HR estimates. Models were adjusted for age (five-year 
age categories), study center, BMI (normal, overweight, obese), percent NA ancestry 
(continuous), parity (categorical), and stage (local, regional, distant).
A major focus of the analysis is the use of the adaptive rank truncated product (ARTP) 
method that utilizes a highly efficient permutation algorithm to determine the significance of 
each gene and of the overall pathway with survival (26, 27). This enables us to focus on the 
significance of the gene and then if genes appear to be significant, we evaluate SNPs that 
contribute to the gene importance. Using ARTP, we permuted the survival 10,000 times in R 
version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). SNP associations 
were assessed among the observed and permuted data in R using p values from likelihood-
ratio tests comparing fully adjusted Cox proportional hazards models to reduced models 
excluding the SNP term. The PARTP is based on assessment of a maximum of five truncation 
points for each gene and for the pathway. Results included in tables are based on statistically 
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significant genes from ARTP analysis (p of 0.05 or less) and statistically significant SNPs (p 
0.05 or less) that contributed to significant gene p values.
Tests for interaction by ancestry and BMI were calculated using a Wald one degree of 
freedom (1-df) test; adjustments for multiple comparisons within the gene used the step-
down Bonferroni correction, taking into account the correlated nature of the data using the 
SNP spectral decomposition method proposed by Nyholt (28) and modified by Li and Ji 
(29).
Results
Approximately the same percentage of women who had low NA ancestry or high NA 
ancestry died during follow-up (Table 1). Breast cancer was the most common cause of 
death among women with low NA ancestry (48.9%) and women with high NA ancestry 
(55.3%) women.
The age, study, menopausal status, and SEER summary stage adjusted HR for all-cause 
mortality for low NA ancestry versus those with high NA ancestry was 1.13 (95% CI 0.93, 
1.38). Further evaluation of all-cause mortality (Table 2) showed that the overall energy 
homeostasis pathway evaluated was marginally significant among women with low NA 
ancestry (PARTP = 0.057). Within the pathway, GHRL and LEPR were significant (PARTP = 
0.035 and 0.007 respectively). Two SNPs were significantly associated with GHRL and 11 
SNPs (three in high LD in our data) were associated with LEPR in at least one ancestry 
group. Although no SNP associations were significantly different by NA ancestry after 
adjustment for multiple comparisons, GHRL rs27647 and LEPR rs970468, rs10749754, 
rs1137101, and rs6588147 were significantly different between ancestry groups prior to 
adjustment for multiple comparisons. Associations did not differ by level of BMI during 
referent year (data not shown).
Breast cancer-specific mortality HR adjusted for age, study, menopausal status and SEER 
summary stage for lower NA ancestry relative to higher NA ancestry was 1.15 (95% CI 
0.87,1.52). Although findings associated with energy homeostasis genes were similar for 
breast cancer-specific mortality as was noted for all-cause mortality, associations were 
slightly stronger and involved more genes in the pathway (Table 3). The overall pathway was 
significantly associated with breast cancer-specific mortality among women with low NA 
ancestry. Three genes, CCK, GHRL, and LEPR were significantly associated with breast 
cancer-specific mortality among women with low NA ancestry (PARTP = 0.046, 0.015, and 
0.046 respectively) and NPY was significantly associated with breast cancer-specific 
mortality among women with higher NA ancestry (PARTP = 0.038). SNPs within these genes 
that were associated with increased likelihood of dying comparing the rare to more common 
homozygote variants (CCK rs747455, GHRL rs35683, rs35682, and rs27647, LEPR 
rs970468, rsrs11585329, rs6588147, and NPY rs16129) and better survival with similar 
comparisons (LEPR rs7526141, rs17412175, rs6704167). Associations did not differ by 
level of BMI during the referent year (data not shown).
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Our study provides support for an association between EH genes and survival after diagnosis 
with breast cancer. GHRL and LEPR appeared to have the greatest influence for both all-
cause mortality and breast cancer-specific mortality, with the strongest associations among 
women with low NA ancestry. CCK influenced breast cancer-specific mortality among 
women with low NA ancestry while NPY influenced breast cancer-specific mortality among 
women with higher NA ancestry. BMI did not appear to modify these associations.
Multiple GHRL SNPs showed significant associations with breast cancer-specific mortality. 
GHRL is a pleiotropic hormone predominately produced in the stomach, and is an 
endogenous ligand for the Growth Hormone Secretagogue Receptor (GHSR) with two major 
functions: the stimulation of growth hormone (GH) production and the stimulation of food 
intake (3). GHRL stimulates the production of GH through the activation of GHSR-1a in the 
hypothalamus and increases appetite and food intake independent of GHSR. In addition to 
its orexigenic function, GHRL also functions in cell proliferation; this function, in 
conjunction with the stimulatory effect on GH secretion from the anterior pituitary renders 
GHRL a potential factor of tumorigenesis (8). Nonetheless, little evidence has thus far been 
produced to show an association between GHRL polymorphisms and survival in breast 
cancer patients. However, GHRL polymorphisms have been associated with obesity (3) and 
recent studies have associated obesity with decreased survival in breast cancer patients (30, 
31), particularly in Hispanics with morbid obesity (18) but these results are far from 
conclusive and are contradicted by other studies (32).
GHRL also plays an important role in the maintenance of the GH-IFG1 axis (3). Thus 
GHRL polymorphisms could alter hepatic IGF-1 expression levels and IGF1 polymorphisms 
and expression have been associated with breast cancer survival (33, 34). Moreover, in 
prostate cancer GHRL is highly expressed and has been shown to initiate cross-talk to 
MAPK signaling cascades, playing an important role in cell proliferation via the activation 
of the ERK1/2 MAPK pathway, but also through an alternative p38 (MAPK14) pathway 
(35). While this cross-talk has yet to be shown in breast cancer tissues, both of these MAPK 
pathways have been associated with breast cancer survival in individuals of lower NA 
ancestry (36), providing a possible explanation for our observed association between GHRL 
and breast cancer survival. GHRL has also been shown to play a role in the pathophysiology 
of cachexia, with cachectic patients having higher GHRL concentrations, while cachexia is 
associated with decreased survival (14). However, other studies have shown that elevated 
GHRL expression is associated with increased survival in non-cachectic patients (13). 
Unfortunately we do not have information about how our associated SNPs affect GHRL 
expression.
LEPR SNPs also showed an association with breast cancer survival. LEPR is a cytokine 
receptor that is highly expressed in multiple tumors, including breast cancer, and in breast 
cancer LEPR expression is directly correlated with poor prognosis (37). LEP is 
predominately secreted by adipose tissue, and functions as an anorexigenic hormone 
responsible for appetite suppression and maintenance of EH. This control of EH is mediated 
via LEP induced proteolytic processing of NPY and POMC in the Arcuate nucleus of the 
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hypothalamus and the subsequent liberation of α-MSH; LEP also negatively regulates the 
orexigenic hormones NPY and Agouti Related Peptide (AgRP) (38). LEP binding to LEPR 
initiates multiple signal cascades to mediate its orexigenic effect, including JAK2/STAT3, 
phosphoinositide 3 kinase (PI3K)/Akt, and ERK MAPK, which can also promote the 
proliferation and survival of cancer cells (37-39). LEP signaling can also mediate anti-
apoptotic effects through the overregulation of bcl-2 and expression of survivin and hey2, 
alter microenvironment to favor growth and progression through increases in MMP2 and E-
caderine, and promote angiogenesis through VEGF and VEGFR2 (38).
Therefore LEP can act as a mitogenic, motogenic, prognostic, and angiogenic factor. LEP 
has also been associated with decreased survival in breast cancer patients (37, 39, 40) and 
with cachexia (14). While we did not duplicate these findings, we showed an association 
between multiple LEPR SNPs and breast cancer survival. Activation of LEPR leads to 
downstream signaling via the ERK1/2 MAPK pathway which has been associated with 
decreased breast cancer survival (36, 41, 42). We have previously reported that this pathway 
is associated with breast cancer survival in patients of low NA ancestry (36), which 
correlates with our findings.
CCK was associated with breast cancer-specific mortality in women of low NA ancestry. 
CCK is important in the control of food intake, reducing food intake and promoting satiety 
(43). However, CCK activation of CCK Receptor A (CCKAR) and CCK Receptor B 
(CCKBR) induces the chemotaxis of monocytes (44). Chronic low grade inflammation, as 
represented by an increased C-reactive protein (CRP), has been negatively associated with 
breast cancer survival (6). Moreover, CCK has been shown to function as an insulin 
secretagogue and islet derived CCK may act locally to prevent β cell apoptosis (45), and 
hyperinsulinemia is an independent risk factor for poor prognosis in women with breast 
cancer(6). It has been hypothesized that women with higher NA ancestry develop type 2 
diabetes mellitus at a younger age and over time become hypoinsulinemic (21). If this 
hypothesis is correct it could explain the lower impact of CCK SNPs on survival in women 
of higher NA ancestry.
NPY rs16129 was significantly associated with survival in women of higher NA ancestry. 
NPY is a 36 amino acid peptide released by sympathetic nerves and is a potent trophic factor 
(46). In the nervous system NPY is a neurotransmitter playing a role in cognitive function, 
feeding behavior and cardiovascular regulation (47). NPY has been shown to increase the 
proliferation and migration of breast cancer cells, angiogenesis, and function in a paracrine 
manner to stimulate the release of cytokines, such as IL-6, IL-8, TNF-α and VEGF (46, 47). 
NPY Y1R, Y2R and Y5R have been reported in breast cancer lines and breast carcinomas 
are reported to have a high density of NPY receptors; Y5R activation stimulates growth 
through increased MAPK activity (7, 47, 48). This in turn leads to increased ERK 1/2 
phosphorylation. Moreover, chronic stress, which is associated with breast cancer risk, leads 
to elevated sympathetic neurotransmitter release and sympathetics arising from the lateral 
and anterior cutaneous branches of the second through the sixth intercostal nerves ensure a 
constant supply of NPY ligands to the breast microenvironment (47). This coupled with the 
high density of NPY receptors may lead to a hyperactivation of the ERK1/2 MAPK system, 
which is associated with adverse clinical features and poor prognosis (42, 49). Poor clinical 
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outcome is in part due to the fact that ERK 1/2 MAPK signaling can prime estrogen receptor 
(ER) signaling, so that overstimulation of the system may drive ER signaling and hence 
tumor growth independent of an estrogen ligand (42); these hormone refractory breast 
cancers respond poorly to hormone ablation therapies.
Our findings show that NPY SNPs are associated with breast cancer-specific mortality in 
women of high NA ancestry. One possible explanation for this association is that chronic 
stress leads to elevated NPY release and that NPY is a potent chemoattractant for monocytes 
when acting through Y2R and Y5R (47). Moreover, NPY acts in a paracrine fashion to 
stimulate the release of TNF-α. We have previously shown that women of higher NA 
ancestry show a greater protective effect with higher intake of dietary antioxidants (50) and 
that TNF SNPs are more strongly associated with breast cancer risk and survival in women 
of higher NA ancestry (51).
The study has both strengths and limitations. First, we used a tagSNP approach to gather 
information on the genetic variation across the gene. Our tagSNP approach was 
implemented on a customized Illumina platform and included SNPs that were validated and 
considered to have a high probability of yielding results. Our tagSNPs were identified using 
the Illuminia data and were based mainly on Caucasian populations. While this approach 
allowed us to evaluate genetic variation across the gene, we may have missed important 
SNPs and therefore important associations. Additionally, we are limited in our knowledge of 
the functionality of these SNPs, which makes it difficult to determine how SNPs operate in 
influencing gene expression or protein levels. We were able to examine associations by NA 
ancestry as well as by BMI, important factors that could modify risk associated with 
survival. We utilized a two ancestry population since this structure best fit our data. While 
we had disease stage data we did not have information on treatment. We used both ARTP 
and Benjamin and Hochberg adjustments for multiple comparisons to identify genes and 
SNPs of importance for survival. However, findings could still be from chance and need 
replication in other ethnically diverse populations.
In summary, our results support our hypothesis that EH genes influence survival after 
diagnosis with breast cancer. GRHL and the LEPR appear to have the most influence on 
survival. CCK and NPY were associated with breast cancer-specific mortality only, while 
LEPR and GHRL showed associations with both all-cause and breast cancer specific 
mortality. The greatest influence of EH genes on survival was found among women with low 
NA ancestry (i.e. mostly European ancestry), although NPY influenced breast cancer-
specific survival among women with high NA ancestry only. Body size did not appear to 
influence these associations with survival. Confirmation of these findings in a similar 
ethnically diverse population is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Description of Study Population by Native American Ancestry
0-28% Native American Ancestry 29-100% Native American Ancestry
N % N %
Study Site
 4-Corners Breast Cancer Study 999 71.31 391 41.60
 San Francisco Bay Area Breast Cancer Study 402 28.69 549 58.40
Age (years)
 24-39 98 7.00 80 8.51
 40-49 384 27.41 317 33.72
 50-59 395 28.19 258 27.45
 60-69 338 24.13 194 20.64
 >70 186 13.28 91 9.68
Menopausal Status
 Pre-menopausal 469 34.41 367 41.01
 Post-menopausal 894 65.59 528 58.99
Self-Reported Race/Ethnicity
 non-Hispanic White 1177 84.01 9 0.96
 Hispanic/Native American 224 15.99 931 99.04
Vital Status
 Deceased 297 21.20 186 19.79
 Alive 1104 78.80 754 80.21
Cause of Death
 Breast Cancer 145 48.82 104 55.91
 Other 152 51.2 82 44.1
SEER Summary Stage
 Local 946 69.10 532 59.91
 Regional 407 29.73 348 39.19
 Distant 16 1.17 8 0.90
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